NPS Takes $145M Advance on Sensipar Royalties from Amgen
By Catherine Shaffer
Wednesday, August 17, 2011
NPS Pharmaceuticals Inc. will receive a $145 million advance on royalties from Sensipar/Mimpara (cinacalcet HCL) sales from partner Amgen Inc. and will retire its 15.5 percent secured class B notes when they become redeemable Sept. 20. The move will save NPS about $13 million in interest expenses over the next two years.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.